European Primary Care Cardiovascular Society

First-in-human study with CRISPR/Cas9-based gene editing in transthyretin amyloidosis with cardiomyopathy

3' education - Nov. 6, 2022 - Prof. Julian D. Gillmore, MD, PhD

CODE-EHR, a framework for the use of electronic health record data in clinical research

5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD

Risk of CVD in patients with autoimmune diseases

5' education - Oct. 12, 2022 - Prof. Naveed Sattar, MD, PhD

DOAC versus VKA in rheumatic atrial fibrillation

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?

3' education - Sep. 5, 2022 - Prof. Marco Valgimigli, MD, PhD

Long-term use of PCSK9i reduces CV events in ASCVD

3' education - Aug. 29, 2022 - Michelle O'Donoghue, MD

smartphone-based screening more than doubles detection rate of atrial fibrillation

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD

A community-based screening trial for CVD

3' education - Aug. 28, 2022 - Prof. Axel Diederichsen, MD

Improved outcomes with SGLT2i in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Patients with heart failure benefit from SGLT2i regardless of ejection fraction

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

ARNI has no negative effect on cognitive function

3' education - Aug. 26, 2022 - Prof. John McMurray, MD

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

What are potential mechanisms of benefit of icosapent ethyl?

10' education - June 20, 2022 - Prof. Chris Packard, PhD

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 2, 2022 - Prof. Richard Hobbs, MD

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Dietary education in the grocery store: a novel form of CV research

3' education - Apr. 19, 2022 - Prof. Eileen Handberg, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Antihypertensive treatment associated with lower risk of dementia

Literature - Nov. 21, 2022 - Peters R et al. - Eur Heart J. 2022

In a meta-analysis of pooled individual participant data from 5 double-blind placebo-controlled RCTs, antihypertensive treatment was associated with a lower dementia risk compared with placebo.

Reduced worsening of kidney disease or CV death by SGLT2 inhibitor in CKD

News - Nov. 7, 2022

AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.

Mindfulness could lower elevated blood pressure

News - Nov. 7, 2022

AHA 2022 By participating in a mindfulness-based program, individuals with elevated office blood pressure (BP) could lower their systolic BP by 4.5 mmHg within 6 months compared with enhanced usual care.

Effect of dietary supplements on cholesterol compared with low-dose statin and placebo

News - Nov. 7, 2022

AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.

CRISPR/Cas9-based gene editing in patients with transthyretin amyloid cardiomyopathy

News - Nov. 6, 2022

AHA 2022 A phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of NTLA-2001, a CRISPR/Cas9-based in vivo gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy.

First-in-human study with CRISPR/Cas9-based gene editing in transthyretin amyloidosis with cardiomyopathy

3' education - Nov. 6, 2022 - Prof. Julian D. Gillmore, MD, PhD
Prof. Gillmore shares the results of a phase 1 study that showed that treatment with the investigational CRISPR/Cas9-based gene editing therapy NTLA-2001 led to a TTR reduction of ≥90% by day 28 in patients with transthyretin amyloidosis with cardiomyopathy.

AHA 2022 Prof. Gillmore shares the results of a phase 1 study that showed that treatment with the investigational CRISPR/Cas9-based gene editing therapy NTLA-2001 led to a TTR reduction of ≥90% by day 28 in patients with transthyretin amyloidosis with cardiomyopathy.

Does low-frequency intermittent fasting reduce LDL-c?

Literature - Oct. 31, 2022 - Bartholomew CL et al. - Eur Heart J Open. 2021

In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.

CODE-EHR, a framework for the use of electronic health record data in clinical research

5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD
What is CODE-EHR and why has this framework been developed? Prof. Asselbergs gives a brief overview in response to questions of Joris Holtrop.

CSI Barcelona What is CODE-EHR and why has this framework been developed? Prof. Asselbergs gives a brief overview in response to questions of Joris Holtrop.

Risk of CVD in patients with autoimmune diseases

5' education - Oct. 12, 2022 - Prof. Naveed Sattar, MD, PhD
What is the risk of CVD in patients with autoimmune diseases and has this yet been incorporated in the guidelines? Marga Helmink interviews Prof. Sattar on this topic.

CSI Barcelona What is the risk of CVD in patients with autoimmune diseases and has this yet been incorporated in the guidelines? Marga Helmink interviews Prof. Sattar on this topic.

Long-term treatment with PCSK9 is safe and reduces LDL-c in in pediatric HeFH patients

Literature - Oct. 7, 2022 - Santos RD, et al. - Lancet Diabetes Endocrinol. 2022

The HAUSER-RCT study showed that in pediatric patients with HeFH, treatment with evolocumab for 24 weeks is safe and reduces LDL-c levels, compared with placebo. But what about the long-term safety and efficacy of evolocumab in this patient population?

Reduced statin eligibility in low-ASCVD-risk European countries by 2021 ESC Guidelines

Literature - Oct. 4, 2022 - Mortensen MB, et al. - JAMA Cardiol. 2022

In a population-based cohort study, the clinical performance of the 2021 ESC Guidelines for CVD prevention on eligibility of primary prevention with statins was compared with that of the 2019 ESC/EAS, 2016 NICE, and 2013 ACC/AHA guidelines.

Improved MI and IHD risk prediction with elevated remnant cholesterol

Literature - Oct. 3, 2022 - Doi T, et al. - J Am Coll Cardiol. 2022

Most guidelines include total cholesterol and HDL-c levels in risk prediction of ischemic and atherosclerotic heart disease, but not remnant cholesterol levels. Does inclusion of elevated remnant cholesterol levels improves prediction?